Dicot Pharma AB OMXSTO:DICOT:
SUBMITS AN IND APPLICATION TO FDA
PREPARING APPLICATION TO EUROPEAN REGULATORY AUTHORITIES
Dicot Pharma Submits IND Application To FDA
Earlier from Dicot Pharma
- Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27
- The subscription period in Dicot Pharma’s rights issue commences today
- Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study
- Dicot Pharma publishes prospectus in connection with the forthcoming rights issue
- Dicot Pharma Resolves On Rights Issue Of About SEK 210 Mln
Later from Dicot Pharma
- DICOT: Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study
- Dicot Pharma announces the final subscription date for units in the ongoing rights issue
- Dicot Pharma announces preliminary outcome in oversubscribed rights issue
- Dicot Pharma presents at Aktiespararnas’ event Aktiedagarna on June 9
- Dicot Pharma Announces Outcome In Oversubscribed Rights Issue
Follow Dicot Pharma into a list and get an email when it puts out news.
Follow Dicot Pharma